STOCK TITAN

BridgeBio Pharma, Inc. - BBIO STOCK NEWS

Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.

The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.

BridgeBio’s robust pipeline boasts several notable programs:

  • Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
  • Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
  • BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.

BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.

Key recent developments include:

  • The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
  • Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
  • Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.

BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary
BridgeBio Pharma will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 10th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
conferences
Rhea-AI Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on April 7, 2023, that it granted restricted stock units totaling 25,900 shares to five new employees. This award was made under the company’s 2019 Inducement Equity Plan and is in compliance with Nasdaq Listing Rule 5635(c)(4). The Plan, established to attract talent, has undergone amendments since its inception in November 2019.

Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and cancers. The company operates a pipeline that spans early research to advanced clinical trials, emphasizing its commitment to genetic medicine and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma announced the initiation of a Phase 1/2 clinical trial for BBP-398, an investigational SHP2 inhibitor, in combination with OPDIVO for treating patients with KRAS-mutated non-small cell lung cancer (NSCLC). The trial aims to evaluate the safety and preliminary efficacy of this combination, targeting a significant unmet medical need as KRAS mutations are present in approximately 27% of NSCLC cases. If successful, this therapy could enhance treatment options for patients with these mutations. Initial data from this trial is expected later in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
-
Rhea-AI Summary

BridgeBio Pharma will present preliminary data on its muscle tissue-based bioassay for LGMD2I patients at the MDA 2023 Annual Meeting from March 19-22 in Dallas, Texas. The company will discuss 15-month Phase 2 data and the design of its Phase 3 clinical trial for BBP-418, expected to start in mid-2023. An oral presentation will be held on March 20, featuring results from the ongoing Phase 2 trial. An investor call with Dr. Jeffrey Rosenfeld is scheduled for March 21 at 8:30 am ET, discussing findings and study updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
Rhea-AI Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced an underwritten public offering of 8,823,530 shares at $17.00 per share, targeting gross proceeds of approximately $150 million. The offering includes a 30-day option for underwriters to purchase an additional 1,323,529 shares. The offering is managed by Goldman Sachs, Evercore ISI, Morgan Stanley, and KKR Capital Markets. Closing is expected around March 10, 2023. The shares are offered under an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or solicit any offers to buy these securities in unlawful jurisdictions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
-
Rhea-AI Summary

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has initiated an underwritten public offering of $150 million in common stock, with an additional $22.5 million option for underwriters. The offering is under the management of Goldman Sachs, Evercore, and Morgan Stanley and is subject to market conditions. The shares are offered under an effective shelf registration statement filed with the SEC in July 2020. A preliminary prospectus supplement detailing the offering will be filed shortly. This announcement does not serve as an offer to sell or solicit purchases in jurisdictions where it would be illegal. BridgeBio is dedicated to advancing treatments for genetic diseases and cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.29%
Tags
-
Rhea-AI Summary

BridgeBio Pharma announced positive results from the PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia. Key findings include:

  • In Cohort 5, a mean increase in annualized height velocity (AHV) of +3.03 cm/yr (p = 0.0022) was observed at the highest dose (0.25 mg/kg once daily).
  • 80% of participants were responders with an average AHV increase of +3.81 cm/yr.
  • Median absolute AHV reached 7.6 cm/yr.
  • Infigratinib showed a clean safety profile with no treatment-related adverse events.
  • BridgeBio is now enrolling for a pivotal Phase 3 trial and exploring infigratinib for hypochondroplasia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.98%
Tags
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced an investor call on March 6, 2023, at 7:30 am ET to discuss Phase 2 Cohort 5 data from the PROPEL2 clinical trial of infigratinib, targeting achondroplasia. Infigratinib is designed to inhibit fibroblast growth factor receptor 3 (FGFR3), addressing a genetic condition affecting ~55,000 in the US and EU. This genetic disorder can lead to serious health complications, emphasizing the importance of continued research and treatment innovation. For more details, visit BridgeBio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
conferences clinical trial

FAQ

What is the current stock price of BridgeBio Pharma (BBIO)?

The current stock price of BridgeBio Pharma (BBIO) is $26.49 as of December 20, 2024.

What is the market cap of BridgeBio Pharma (BBIO)?

The market cap of BridgeBio Pharma (BBIO) is approximately 5.0B.

What does BridgeBio Pharma, Inc. specialize in?

BridgeBio Pharma specializes in discovering, creating, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers.

What are the core focus areas of BridgeBio Pharma's pipeline?

The core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy.

What are some key programs in BridgeBio's pipeline?

Key programs include acoramidis (AG10) for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, and BBP-418 for LGMD2I/R9.

What recent financial achievements has BridgeBio Pharma accomplished?

BridgeBio recently completed a $200 million private financing for its oncology subsidiary and has conducted multiple public offerings.

Has BridgeBio Pharma formed any significant partnerships?

Yes, BridgeBio has partnered with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets.

What recent clinical trial results has BridgeBio Pharma announced?

BridgeBio announced positive results from the Phase 3 ATTRibute-CM trial for acoramidis, showing significant improvements in health-related quality of life for patients with ATTR-CM.

When was BridgeBio Pharma founded?

BridgeBio Pharma was founded in 2015.

Where is BridgeBio Pharma headquartered?

BridgeBio Pharma is headquartered in Palo Alto, California.

What is the therapeutic approach of BridgeBio Pharma?

BridgeBio Pharma applies a systematic mapping of the genetic disease landscape to identify promising therapeutic assets and leverages its proprietary platform to develop these assets into impactful treatments.

How can I learn more about BridgeBio Pharma’s developments?

For more information, visit bridgebio.com and follow BridgeBio on LinkedIn and Twitter.

BridgeBio Pharma, Inc.

Nasdaq:BBIO

BBIO Rankings

BBIO Stock Data

4.98B
149.78M
5.4%
94.16%
9.09%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PALO ALTO